Collectively, these results provide strong evidence that mutations in BRCA2 and HOXB13 are associated with an increased risk of prostate cancer and highlight their role as potential genetic markers for early detection and risk stratification. This evidence concerns the gene BRCA2 and prostate carcinoma.